Financial Performance - Revenue increased from RMB 113.7 million in 2022 to RMB 204.0 million in 2023, marking a growth rate of 79.5%[11]. - The company reported a pre-tax loss of RMB 145.859 million in 2023, an improvement from a loss of RMB 182.740 million in 2022[20]. - The annual loss attributable to equity holders of the parent was RMB 132,533,000, compared to RMB 180,003,000 in the previous year, indicating a decrease in losses[171]. - Gross profit for the same period was RMB 125,133,000, up from RMB 55,852,000, reflecting a significant improvement in profitability[171]. - The total comprehensive loss for the year ended December 31, 2023, was RMB 146,824,000, compared to RMB 182,730,000 in 2022, indicating an improvement[198]. Customer and Market Growth - The number of customers grew to 673, representing a year-on-year increase of 69.5%[4]. - The company’s active service points increased from 2,371 to 5,671, reflecting a strategic expansion in service delivery[11]. - The number of active coverage points for Airdoc-AIFUNDUS (1.0) in hospitals reached 276, a year-on-year increase of 527.3%, with testing frequency reaching 242,000, up 197.5%[53]. - The number of active grassroots medical institution points for Airdoc-AIFUNDUS (1.0) reached 1,221, a year-on-year increase of 1,271.9%, with testing frequency reaching 635,000, up 640.2%[21]. Product Development and Innovation - The company expanded its product portfolio to include myopia prevention AI products and visual training AI products, with usage reaching 890,300 times for myopia prevention and 918,400 training sessions for visual training[5]. - The company participated in the development of an expert consensus on assessing cardiovascular disease risk using AI technology based on fundus images, highlighting its innovative approach in the field[7]. - Airdoc-AIFUNDUS (1.0) received CE MDR certification in 2023, allowing entry into 27 EU member states, including Belgium, Germany, Italy, and France[28]. - The company has developed three self-owned retinal cameras that integrate AI technology, providing a comprehensive healthcare solution combining hardware and software[38]. Research and Development - Eight papers were accepted at the MICCAI 2023 conference, including one oral presentation, highlighting the company's research contributions in medical image analysis[25]. - The company developed a deep learning model for screening hyperthyroidism, marking a global first in non-invasive diagnosis using retinal imaging[74]. - The AI algorithm model developed by the company demonstrated excellent performance, with an AUC of 0.976 in internal validation and 0.86 in external validation among the elderly population[71]. - Research and development expenses decreased to RMB 111,642,000 from RMB 125,594,000, showing a reduction of 11.1%[171]. Financial Position and Assets - The company’s non-current assets increased significantly to RMB 402.985 million in 2023 from RMB 64.137 million in 2022[20]. - The company’s net asset value decreased to RMB 1,557.784 million in 2023 from RMB 1,671.362 million in 2022[20]. - Current assets totaled RMB 1,281.9 million as of December 31, 2023, with cash and cash equivalents at RMB 891.5 million[115]. - Accounts receivable increased from RMB 639 million as of December 31, 2022, to RMB 796 million as of December 31, 2023, due to faster collection from customers[91]. Strategic Initiatives - The company aims to include Airdoc-AIFUNDUS (1.0) in pricing guidelines across most provinces in China, allowing hospitals to charge patients for these services[52]. - The company plans to expand its health risk assessment solutions to include additional risks such as hyperthyroidism and Parkinson's disease[61]. - The company aims to leverage its advanced R&D capabilities to gain a competitive advantage in a market with reduced competition due to stricter regulations[54]. - The company plans to enhance its product offerings by integrating artificial general intelligence (AGI) into its services for improved patient-doctor connectivity[120]. Awards and Recognition - The company’s AI-FUNDUSCAMERA-P and myopia treatment products received special recognition at the Geneva International Invention Exhibition in April 2023, indicating strong global acknowledgment[6]. - The AI-FUNDUSCAMERA-P and myopia treatment products won a "Special Recognition Gold Award" at the Geneva International Exhibition of Inventions in April 2023[28]. Employee and Operational Metrics - As of December 31, 2023, the marketing team consists of 138 members, providing customized support throughout the product lifecycle[51]. - The group has 339 full-time employees as of December 31, 2023, an increase from 275 employees in 2022[160]. - The total salary cost for the group for the year ending December 31, 2023, was RMB 214.1 million, a slight decrease from RMB 216.0 million in 2022[141].
鹰瞳科技-B(02251) - 2023 - 年度业绩